|1.||Said, Harun M: 3 articles (07/2013 - 01/2007)|
|2.||Flentje, Michael: 3 articles (07/2013 - 01/2007)|
|3.||Staab, Adrian: 3 articles (07/2013 - 01/2007)|
|4.||Katzer, Astrid: 3 articles (07/2013 - 01/2007)|
|5.||Vordermark, Dirk: 3 articles (01/2010 - 01/2007)|
|6.||Anacker, Jelena: 2 articles (07/2013 - 01/2010)|
|7.||Scozzafava, Andrea: 2 articles (07/2013 - 01/2010)|
|8.||Supuran, Claudiu T: 2 articles (07/2013 - 01/2010)|
|9.||Kim, Catherine: 1 article (09/2015)|
|10.||Bharti, Kapil: 1 article (09/2015)|
07/01/2013 - "application was at a range between 250 and 8000 nM and the HIF-1α inhibitor Chetomin at a concentration range of 150-500 nM. Cell culture plates were incubated for 24 h under hypoxia (0.1% O2). "
02/01/2011 - "Here, we report that chetomin, an inhibitor of hypoxia-inducible factors, is a potent enhancer of TRAIL-induced apoptosis. "
11/01/2006 - "Inhibition of HIF activity using a small-molecule inhibitor, chetomin, enhanced cellular sensitivity to VSV, while treatment with hypoxia mimetic CoCl2 promoted resistance. "
07/01/2004 - "At a molecular level, chetomin disrupts the structure of the CH1 domain of p300 and precludes its interaction with HIF, thereby attenuating hypoxia-inducible transcription. "
01/01/2007 - "HIF-1 inhibition by chetomin effectively reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro."
10/21/2014 - "Chetomin is a promising molecule with anti-tumor activities in the epipolythiodioxopiperazine family of fungal secondary metabolites; however, strong hydrophobicity has limited its further applications. "
07/01/2013 - "Aza., SU.D2, Chetomin or CA9-siRNA possesses functional CA9 inhibitory characteristics when applied against human cancers with hypoxic regions like GBM. "
01/01/2010 - "These may be used as alternative or in conjunction with other direct inhibitors like the sulphonamide derivate compounds, chetomin or specific siRNAs, or other different chemical compounds possessing similar functionality making them as optimal tools for optimized therapy development in cancer treatment, especially against human brain cancer. "
07/01/2004 - "Systemic administration of chetomin inhibited hypoxia-inducible transcription within tumors and inhibited tumor growth. "
01/01/2010 - "HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression."
12/01/2009 - "Administration of chetomin in combination with forskolin significantly suppresses malignant glioma growth in an in vivo xenograft model. "
01/01/2010 - "Although siRNA and chetomin show distinct modes of action, both attenuated the hypoxia-induced radioresistance of malignant glioma cell lines U251MG (DMF10: 1.35 and 1.18) and U343MG (DMF10: 1.78 and 1.48). "
02/01/2011 - "Taken together, these findings suggest that TRAIL and chetomin synergistically induce apoptosis in human urogenital cancer cells through a mechanism that involves XIAP down-regulation by chetomin."
02/01/2011 - "Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells."
|5.||Prostatic Neoplasms (Prostate Cancer)
|2.||Small Interfering RNA (siRNA)
|3.||Transcription Factors (Transcription Factor)
|4.||Hypoxia-Inducible Factor 1
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Messenger RNA (mRNA)
|1.||Heterologous Transplantation (Xenotransplantation)